All In Biotech

Drug Trial Radar · NCT06593392

Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus

An Open-label, Single-arm Study to Evaluate the Safety and Tolerability of Intravenous Difelikefalin in Adolescents Aged 12 to 17 Years on Haemodialysis With Moderate-to-Severe Pruritus (KOR-PED-202)

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Aug 4, 2026

Primary completion

Aug 15, 2029

Study completion Aug 15, 2029

Sponsor

Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Rationale: * People with long term kidney disease who are on haemodialysis (a procedure for removing waste products from the blood) commonly develop a condition that makes their skin very itchy. * Difelikefalin is a medicine that can treat the itching related to long term kidney disease. * Clinical studies have shown difelikefalin to reduce itching in adults on haemodialysis, while being safe and tolerable. * The current study is being done in adolescents aged 12 to 17 years on haemodialysis who have moderate to severe itching related to long term kidney disease to assess if difelikefalin is safe in this age group. The aims of the study are: Main aim: To assess the safety of difelikefalin in adolescents who are on haemodialysis and have itching related to long term kidney disease Secondary aim: To measure the amount of difelikefalin that enters the blood in adolescents who are on haemodialysis and have itching related to long term kidney disease Study Design At least 18 adolescents, aged 12 to 17 years, who are on haemodialysis and have itching related to long term kidney disease will take part in this study. All study participants will receive difelikefalin 3 (or up to 4) times weekly for up to 12 weeks. The study duration for a participant is up to 17 to 18 weeks; during this period, participants will visit the clinic 3 times weekly (during their haemodialysis visits).

Conditions

  • Pruritus
  • Chronic Kidney Diseases

Interventions

  • DifelikefalinDrug

    The study includes a screening period of up to 4 weeks (including a 7-day run-in period during the week prior to enrolment), a study treatment period of 12 weeks, and a safety follow-up visit at 7 (up to 10) days after EoT. Total study duration for a single participant is up to 17 to 18 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs)Time frame: Up to 18 weeks

Locations

18 sites in 7 countries. Site status is shown where the registry gives one.

  • Sichuan University-West China Second University Hospital

    Chengdu, China · Recruiting

  • The First Affiliated Hospital, Sun Yat-sen University

    Guangzhou, China · Recruiting

  • Guangzhou Women and Children's Medical Center

    Guangzhou, China · Recruiting

  • The Children's Hospital Zhejiang University School of Medicine

    Hangzhou, China · Recruiting

  • The Children's Hospital of Fudan University

    Shanghai, China · Recruiting

  • Huazhong University of Science and Technology-Tongji Medical College-The Central Hospital of Wuhan

    Wuhan, China · Recruiting

  • Xi'an Children's Hospital

    Xi'an, China · Recruiting

  • Pan and Aglaia Kyriakou Children's Hospital

    Athens, Greece · Recruiting

  • Shaare Zedek Medical Center

    Jerusalem, Israel · Recruiting

  • Schneider Children's Medical Center of Israel

    Petah Tikva, Israel · Recruiting

  • King Faisal Specialist Hospital and Research Center, Riyadh

    Riyadh, Saudi Arabia · Recruiting

  • King Abdullah Specialized Children's Hospital (KASCH)

    Riyadh, Saudi Arabia · Recruiting

  • Hospital Sant Joan de Déu

    Barcelona, Spain · Recruiting

  • Hospital Universitario Valle de Hebron

    Barcelona, Spain · Recruiting

  • La Paz University Hospital

    Madrid, Spain · Recruiting

  • Jalila Children's Specialty Hospital

    Dubai, United Arab Emirates · Recruiting

  • Royal Hospital for Children Glasgow

    Glasgow, United Kingdom · Recruiting

  • Alder Hey Childrens NHS Foundation Trust

    Liverpool, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.